Skip to main content
Clinical Trials/ISRCTN17419165
ISRCTN17419165
Active, not recruiting
未知

Blood-brain barrier permeability, inflammation, and clinical progression in Alzheimer's disease

niversity of Southampton0 sites70 target enrollmentMay 21, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Southampton
Enrollment
70
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 21, 2024
End Date
February 22, 2028
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Southampton

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \> 50 years old, no upper limit.
  • 2\. Able and willing to give informed consent for participation in the study at baseline.
  • 3\. AD participants: meet international consensus criteria for a diagnosis of AD dementia or mild cognitive impairment secondary to AD.
  • Control participants: no cognitive impairment and a MoCA score greater than, or equal to, 26 at baseline.

Exclusion Criteria

  • 1\. Lack capacity to provide informed consent at baseline or decline to participate.
  • 2\. Not proficient in English language.
  • 3\. Absence of a reliable study partner (AD participants only).
  • 4\. Diagnosis of mixed dementia or another central nervous system disease (e.g. multiple sclerosis, stroke).
  • 5\. Intercurrent acute kidney injury, infection, or delirium.
  • 6\. History or presence of major psychiatric disorder or alcohol/substance misuse, within the last two years.
  • 7\. Diagnosis of any severe inflammatory disorder (e.g. rheumatoid arthritis, periodontitis, inflammatory bowel disease, chronic/recurrent gingivitis).
  • 8\. Use of non\-topical steroids or cytokine modulators.
  • 9\. Previous brain imaging showing confluent white matter changes reflective of gross cerebrovascular disease.
  • 10\. Impaired renal function that absolutely contraindicates contrast\-enhanced MRI (eGFR \< 40\).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Blood brain barrier permeability and inflammatory biomarkers in patients with depressioF32.2F32.3F33.2F33.3Severe depressive episode without psychotic symptomsSevere depressive episode with psychotic symptomsRecurrent depressive disorder, current episode severe without psychotic symptomsRecurrent depressive disorder, current episode severe with psychotic symptoms
DRKS00022091Klinik für Psychiatrie, Psychosomatik und PsychotherapieUniversitätsklinikum Frankfurt100
Recruiting
Not Applicable
Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s diseaseneurodegeneratieve aandoeningenAlzheimer's diseasedementia
NL-OMON38302niversiteit Maastricht60
Recruiting
Not Applicable
Quantitative blood-brain barrier permeability and susceptibility mapping for patients with CADASIL and suspected to have CADASICADASI
JPRN-UMIN000035081agoya City University40
Active, not recruiting
Not Applicable
Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning - Escitaloprame, sleep, blood-brain-barrierEffects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 gene
EUCTR2006-001491-21-DEMax Planck Institute of Psychiatry58
Completed
Not Applicable
Blood-Brain Barrier permeability quantification in cerebral small vessel disease -- reproducibility of dynamic contrast-enhanced MRICerebral small vessel diseasedisease of the small brain arteries10007963
NL-OMON38519Medisch Universitair Ziekenhuis Maastricht20